Cancer Research The Future of Cancer Research: Science and Patient Impact 09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 5572-5577, November 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hashimoto, T.
Right arrow Articles by Tsuchiya, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hashimoto, T.
Right arrow Articles by Tsuchiya, E.
[Cancer Research 59, 5572-5577, November 1, 1999]
© 1999 American Association for Cancer Research

Molecular Biology and Genetics

p53 Null Mutations Undetected by Immunohistochemical Staining Predict a Poor Outcome with Early-Stage Non-Small Cell Lung Carcinomas1

Takehisa Hashimoto, Yoshio Tokuchi, Moriaki Hayashi, Yasuhito Kobayashi, Kazunori Nishida, Shin-ichi Hayashi, Yuichi Ishikawa, Shigehiro Tsuchiya, Ken Nakagawa, Jun-ichi Hayashi and Eiju Tsuchiya2

Laboratory of Cancer Diagnosis and Therapy, Saitama Cancer Center Research Institute, Saitama 362-0806, Japan [T. H., Y. T., M. H., S. H., E. T.]; Department of Pathology, Saitama Cancer Center Hospital, Saitama 362-0806, Japan [Y. K., K. Ni., E. T.]; Department of Pathology, Cancer Institute, Tokyo 170-0012, Japan [Y. I.]; Department of Chest Surgery, Cancer Institute Hospital, Tokyo 170-0012, Japan [S. T., K. Na.]; Department of Thoracic and Cardiovascular Surgery, Niigata University School of Medicine, Niigata 951-8122, Japan [T. H., J. H.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The importance of p53 mutations in the pathogenesis of human lung carcinoma is well established, but it is still controversial whether the presence of p53 mutations or overexpression of p53 protein adversely affects an individual patient’s chances of survival. The controversy may be partially due to the methodological differences in examination for p53 alterations: gene analysis or immunohistochemical staining. Furthermore, recent studies have suggested that different types of mutations of the p53 tumor suppressor gene confer different biological properties. To clarify the relationship between immunohistochemical staining and prognosis, we investigated mutations using single-strand conformation polymorphism followed by sequencing for exons 4–8 and 10 in 144 surgically treated non-small cell lung carcinoma patients with intensive clinical follow-up. Of 144 cases, 107 adenocarcinomas were examined for immunohistochemical staining with RSP53 antibody. p53 gene mutations were observed in 65 tumors (45%), including 44 missense and 21 null mutations, the latter comprising 7 nonsense mutations, 8 deletions, 2 insertions, and 4 splicing junction mutations. Presence of p53 mutations was an independent prognostic factor with a statistical trend (P = 0.14) in stage I patients but not in all cases. When examined by mutational pattern, null mutation was a significant indicator of poor outcome by multivariate analysis (P = 0.03) in stage I patients, whereas cases with missense mutations and without mutations did not differ (P = 0.76). Forty (37%) tumors demonstrated overexpression of the p53 protein but without any survival difference. Most tumors (76%) with missense mutations were immunopositive, but those with null mutations with one exception (93%) were not, and the concordance between the mutations and immunohistochemical staining was rather low at 65%. These data suggest that the type of p53 mutation is important for prediction of outcome in early-stage non-small cell lung carcinoma patients, whereas immunohistochemical staining for abnormal p53 gene products is nonpredictive. Furthermore, null mutations causing loss of function of the gene product may play more important roles than missense mutations in tumor progression.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Lung cancer is one of the leading causes of cancer mortality in the world (1 , 2) , and its incidence is increasing in Japan (3) . Histologically, lung cancer is classified into two main types: small cell lung carcinomas and the NSCLCs,3 consisting of adenocarcinomas, squamous cell carcinomas, large cell carcinomas, and other rare types (2 , 4) . The long-term survival rate of NSCLC patients remains unsatisfactory, even when they undergo complete and potentially curative surgery (5) . Therefore, there is an urgent need for new strategies aimed to improve lung cancer management. However, it is often difficult to distinguish unfavorable patients from others with a better prognosis based on the existing diagnostic and management tools. Recent advances of molecular biology and genetics have raised the possibility of new diagnostic techniques and treatment for application in clinical oncology. If individuals with a poor prognosis could be classified at surgery by use of molecular biological techniques, there is a possibility that their survival might be improved by more aggressive adjuvant chemotherapy or innovative gene therapy.

The normal p53 protein has important functions in cell-cycle checkpoints and modulates such important events as G1 arrest, DNA repair, and apoptosis (6, 7, 8) . Alterations of the p53 gene could play crucial roles in the genesis of carcinomas and have been shown to be one of the most common molecular biological changes in various human neoplasms, including NSCLCs (7, 8, 9, 10) . More than 85% of the mutations have been reported in exons 5–8, most being missense mutations (7 , 8) . Most mutant p53 proteins produced by missense mutations are resistant to degradation and thus have prolonged half-lives, allowing their detection by immunohistochemical staining. Accordingly, many investigators have used this approach as a screening method to identify p53 alterations in tumor samples (7 , 8 , 11) . On the other hand, null mutations (nonsense, deletions, insertions, and splicing junction mutations) are less common in exons 5–8 but predominate outside these exons, resulting in premature stop codons and shortened protein products that often may not be detectable by immunohistochemical staining (8 , 12, 13, 14) .

In NSCLCs, there have been many studies of the relationship between p53 alterations and prognosis (15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28) . However, those have yielded conflicting results, and thus, the clinical importance of p53 alterations as a prognostic factor remains controversial. This may be partially due to methodological differences in examination for p53 gene alterations; many authors used immunohistochemistry (15, 16, 17 , 21, 22, 23, 24, 25) , but others used DNA analysis, such as SSCP, with or without sequencing, and discordance among findings with these methods has been reported (11, 12, 13, 14 , 26 , 29 , 30) .

To clarify the relationship between p53 mutations, especially the type of mutation, and immunohistochemical staining as well as prognosis, we have investigated mutations in exons 4–8 and 10 by DNA sequencing and p53 protein accumulation using immunohistochemistry with a series of surgically treated NSCLC specimens. Correlations of the results with patients’ survival rates were also examined.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Tumor Samples and Clinicopathological Data.
p53 alterations were examined in a series of 151 NSCLCs (113 adenocarcinomas and 38 squamous cell carcinomas) that were not accompanied by other primary malignancies and were resected consecutively from 1989 to 1993 at the Cancer Institute Hospital, Tokyo, Japan. Of the patients, seven were excluded from the analyses of survival: three did not have a sufficiently detailed follow-up, two suffered operation-related deaths within 30 days, and two were other hospital mortalities. The remaining 144 patients were eligible for evaluation of survival. All patients analyzed had undergone a potentially curative resection with lobectomy or pneumonectomy, combined with pulmonary hilar and mediastinal lymph node dissection. None had received chemotherapy or radiotherapy before surgery, but 76 (53%) patients had received postoperative adjuvant therapy. Survival duration was calculated from the date of operation until the date of the last follow-up or the date of death. The overall survival was used as an end point. Complete follow-up information was available on all of these 144 patients, with median follow-up periods of 61 months (range, 2–84 months).

The 144 patients included 92 men and 52 women, and the mean patient age at surgery was 62 years (range, 26–84 years; Table 1Citation ). Histopathological classification and differentiation of the tumors was determined by two of the authors (E. T., Y. I.) according to the 1981 WHO classification of lung tumors (4) . There were 107 adenocarcinoma and 37 squamous cell carcinoma patients, with 43 well, 76 moderate, and 25 poorly differentiated carcinomas. According to the TNM staging system of the Union International Contre le Cancer (31) , 68 patients were p stage I, 16 were p stage II, 39 were p stage IIIA, and 21 were p stage IIIB. Finally, p stages were divided into two groups: p stage I, and p stage II-IIIB (68 and 76 patients, respectively). The patient’s smoking history (number of cigarettes per day, starting age, and duration of smoking) was obtained from preoperative personal interviews, with division into nonsmokers without any past history of smoking and smokers, including both patients with a past history of the habit and current smokers (Table 1)Citation .


View this table:
[in this window]
[in a new window]
  		Table 1 Relationships between p53 mutations and clinical characteristics

 
DNA Preparation, p53 Mutation Analysis, and DNA Sequencing.
Fresh tumor samples paired with corresponding noncancerous tissue were obtained from all patients, and then quickly frozen in liquid nitrogen and stored at -80°C until analysis, as described previously (32) . Genomic DNAs were prepared. Exons 4–8 and 10 of p53 were analyzed by the PCR-SSCP method (33) . Coding sequences including exon-intron boundaries were amplified by PCR with the primers and PCR conditions described previously (34) . The 5' ends of each sense and antisense primer were labeled with 6-carboxyfluorescein and 4,7,2',7'-tetrachloro-6-carboxyfluorescein (Japan Bio Service Corp., Asaka, Japan), respectively. SSCP was performed at 22°C, with loading onto nondenaturing 4% polyacrylamide gels with 10% glycerol, and analyzed by ABI PRISM 377 (Perkin-Elmer Corp.). When genomic DNA extracted from tumors showed a different SSCP pattern from corresponding normal lung tissues, both genomic DNAs were amplified with the primers in the presence of [{alpha}-32P]dCTP to elute the shifted DNA fragment for sequence analysis. After PCR under the same cycle conditions, PCR products were electrophoresed in a nondenaturing 5% polyacrylamide gel with 10% glycerol at the most suitable temperature and 35 W constant power for 2–3 h. Gels were subjected to drying at 80°C for 1 h and autoradiographed at room temperature overnight. Both normal and abnormal DNA fragments were eluted from the dried gels and reamplified by PCR with the same primers and PCR conditions. To characterize p53 gene mutations, the reamplified DNAs were sequenced using a dRhodamine terminator cycle sequencing kit (Applied Biosystems Inc.) and ABI PRISM 377.

Immunohistochemical Staining.
Sections (4 µm thick) of formalin-fixed, paraffin-embedded tissue, including large cut surfaces of adenocarcinomas, were immunohistochemically stained by the avidin-biotin peroxidase complex method. RSP53 (Nichirei Corp., Tokyo, Japan), a rabbit polyclonal antibody recognizing a linear epitope in human p53 located between amino acids 54–69 and generally used in Japan (35, 36, 37) , was used as the first antibody. It recognizes both wild-type and mutant p53 protein.

After deparaffinization, the sections were immersed in 0.3% hydrogen peroxide in methanol for 30 min and incubated overnight at 4°C with the primary antibody RSP53. The slides were then washed in PBS and exposed to the secondary antibody, biotinylated swine antirabbit immunoglobulin (DAKO, Glostrup, Denmark), for 1 h at room temperature. Finally, the slides were again washed in PBS and incubated for 30 min with avidin-biotin-peroxidase complex (DAKO), and the peroxidase color reaction was developed. For microscopic examination, the slides were counterstained with Harris’ hematoxylin. Normal rabbit IgG at the same concentration as the primary antibodies served as a negative control. Immunohistochemical reactions were considered positive if more than 15% of the nuclei were stained.

Statistical Analysis.
To assess any correlations between frequencies or types of mutation (missense mutation or null mutation) and clinicopathological data, the {chi}2 test, Fisher’s exact probability test, and Student’s t test were used, with P < 0.05 indicating a significant difference. Survival curves were created by the Kaplan-Meier method, and the statistical significance of differences was calculated by the log-rank test. Multivariate analyses were performed to identify independent prognostic factors and to assess relative risk using the Cox proportional hazards model with the Statistical Package for Social Science (SPSS). In this model, seven factors potentially related to survival (age at surgery, sex, histology, differentiation of the tumor, p stage, smoking status, and p53 status) were included, and the model selection for identifying the subset of significant variables was based on the stepwise method for backward selection.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
p53 Mutations and Relationship with Clinicopathological Parameters.
Of the 144 NSCLCs examined, 65 samples (45%) had a mutation of the p53 gene in exons 4–8 or 10: 3 (5%) located in exon 4; 16 (25%) in exon 5; 9 (14%) in exon 6; 15 (23%) in exon 7; 14 (22%) in exon 8; 4 (6%) in exon 10; and 4 (6%) in splicing junctions (Table 2)Citation . No mutations were found in normal lung tissue samples, except with patients carrying a polymorphism in exon 4, codon 72 (data not shown; Ref 38 ). p53 gene mutations were more frequent in squamous cell carcinomas than in adenocarcinomas, as reported previously (Table 1Citation ; Refs. 8 , 39 ). There was no difference in mean age between p53-positive and -negative status. Tendencies toward more frequent mutations in males than in females and in smokers than in nonsmokers were observed. Frequencies of mutations did not differ with differentiation status, even when tumors were divided into the two histological types (data not shown). Mutations were observed significantly more frequently in p stage II-IIIB than in p stage I patients (P = 0.01).


View this table:
[in this window]
[in a new window]
  		Table 2 Summary of p53 alterations and clinicopathological data

 
When mutations were classified into two types, missense and null, there were 44 (68%) and 21 (32%), respectively, the latter including 7 nonsense mutations, 8 deletions, 2 insertions, and 4 mutations at splicing junctions (Table 1)Citation . There was no mean age difference between the two types. In addition, proportions did not differ significantly with sex, histology, differentiation status, or p stage. A higher proportion of null mutations was observed in smokers than in nonsmokers with statistical significance (P = 0.04).

Immunohistochemical Staining and the Relation to p53 Mutations.
To clarify the relationships between p53 mutations and type and immunohistochemical staining, adenocarcinomas, which were the major cohort in this study, were stained immunohistochemically (Table 3)Citation . Forty (37%) of 107 adenocarcinomas were positive. Although a statistically significant correlation was found between p53 mutations and immunohistochemical staining, 20 (47%) of the 43 mutated tumors were not positive and the concordance rate between immunohistochemical staining and mutation was only 65%. When the p53 gene abnormality was confined to exons 5–8, it increased to 68%. Immunohistochemical staining was detected in only 7% of cases with null mutations but in 76% of those with missense mutations. No relationship was found between immunohistochemical results and clinicopathological parameters (data not shown).


View this table:
[in this window]
[in a new window]
  		Table 3 Correlation between p53 mutation and immunohistochemical staining of adenocarcinomas

 
Survival and p53 Status.
Examination of the relationships between p53 alterations and overall survival, using the Kaplan-Meier method and the log-rank test, revealed a shorter survival period for the 144 NSCLC patients with than those without p53 mutations (P = 0.042; Fig. 1ACitation ). However, considering the strong correlation between frequency of the p53 gene mutation and the tumor stage, we separated the patients into two groups, p stage I and p stage II-IIIB patients. In the 68 p stage I NSCLC patients, there was a trend toward poorer prognosis for those with p53 mutations (P = 0.117; Fig. 1BCitation ). In p stage II-IIIB patients, there was no difference in survival (P = 0.845). There was no difference in survival between immunohistochemically positive and negative adenocarcinomas in all cases, in p stage I and in p stage II-IIIB (P = 0.364, 0.230, and 0.667, respectively; Fig. 1CCitation ).



View larger version (17K):
[in this window]
[in a new window]
  		Fig. 1. Kaplan-Meier survival curves with respect to overall survival. For patients with and without p53 mutation in all p stages (A), in p stage I (B), with and without overexpression in adenocarcinomas of p stage I (C), and without p53 mutations but with missense mutations and null mutations in p stage I (D). A, a worse prognosis was observed in patients with the mutation (P = 0.042). B, a trend toward poorer prognosis in patients with mutations was observed (P = 0.117). C, no difference was observed with immunohistochemical staining (P = 0.230). D, the worst prognosis was observed in patients with a null mutation, the difference from those lacking a mutation being significant (P = 0.008). There was also a trend toward poorer prognosis in patients with null mutations than those with missense mutations (P = 0.079).

 
Finally, we studied the relationship between the type of p53 mutations and survival by stage. Interestingly, in stage I, patients with null mutations showed a shorter survival than those without mutations (P = 0.008) and than those with missense mutations, although this latter difference did not reach statistical significance (P = 0.079; Fig. 1DCitation ). There was no difference in survival between patients with missense mutations and those without mutations (P = 0.802). In p-stage II-IIIB patients, there were no correlations between types of mutations and survival period (data not shown). We also investigated which exon or domain had the most important influence on prognosis, but no associations could be found.

Multivariate analysis of age, sex, histology, tumor differentiation, p stage, and the presence or the types of the p53 gene mutation was performed to examine the interrelationship of possible prognostic factors and survival (Table 4)Citation . In all cases, p53 mutation and its types were not independent prognostic factors. However, in p stage I patients, the presence of a p53 mutation was an independent prognostic factor with a statistical trend (P = 0.14). Furthermore, a null mutation independently predicted poor survival for p stage I patients with a relative risk of 4.30 (P = 0.03).


View this table:
[in this window]
[in a new window]
  		Table 4 Results of multivariate analysis in NSCLC patients evaluated for overall survival

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Many p53 mutational analyses have been performed for various tumors, and it has been reported that most mutations occur in exons 5–8, in so-called "hot-spots" (7 , 8) . However, we added exons 4 and 10, which were mutated most frequently after exons 5–8 in the present study. The observed frequencies of p53 mutations were similar to those of Japanese reports, in which mutations on exons 2–11 were studied extensively in NSCLC patients (28 , 39) . Therefore, we consider that almost all mutations presenting in lung cancers could be found in the present study and that our examined cases are representative for p53 mutations in NSCLCs in Japan. When the proportions of each mutational type were analyzed, null mutations constituted 32%, in line with previous studies (20–42%; Refs. 12, 13, 14 , 27 , 28 ).

The significantly poor clinical evolution observed for patients with a null mutation, but not with a missense mutation, in p stage I might be associated with the following. Null mutations generally cause loss of the COOH-terminal domain of the p53 protein, which plays an important role in tumor genesis. Thus, it has been reported that a synthetic peptide derived from the p53 COOH-terminal domain can restore the transactivation function of at least some mutant p53 proteins in living cells and further cause growth inhibition and apoptosis in a mutant p53-carrying human tumor cell line (40) . Another study demonstrated that COOH-terminal domain mutants, especially oligomerization-defective mutant 342-stop, did not exhibit sequence-specific DNA binding or failed to transactivate p21Waf1/Cip1, Bax, and IGF-BP3 transcriptionally (41) . Thus, loss of COOH-terminal domain may equal loss of p53 gene function. On the other hand, with a significant number of missense mutations, the ability to bind DNA and form tetramers is retained, so that a part of the gene function may remain.

One earlier report suggested that null mutations predict a poor outcome in NSCLC patients, but the result was negated by multivariate analysis (27) . Thus, this is the first clear demonstration by multivariate analysis in a large cohort of patients with adequate staging and follow-up that null mutations can predict a poor outcome. There has been a report that missense mutations predict poor outcome in stage I NSCLC patients (28) , but this is not in conformity with the functional properties of p53 mutant proteins described above. Further analysis of a larger number of patients, possibly in a prospective fashion, is now required to elucidate the prognostic impact of p53 null mutations and missense mutations in NSCLC patients.

In the present study, p53 mutations were related to a poor prognosis only in p stage I NSCLC patients but not in those with p stage II or more advanced stage disease. This may be explained as follows. Malignancy in a tumor increases with successive alterations of oncogenes and tumor suppressor genes. In the early stages of NSCLC, the numbers of such altered genes are still small, and accordingly, loss of p53 function exerts a large effect. However, in late or advanced stage malignancies, the presence of large numbers of accumulated alterations means that the effect of p53 dysfunction is relatively minor.

The frequency of p53 immunohistochemical staining in this study was in accordance with previous findings for lung adenocarcinomas (24 , 26 , 37) , and the concordance rate with p53 mutations was also similar to those in the literature (20 , 26 , 28) . All null mutations except one were immunonegative, perhaps explaining controversial results regarding prognosis related to p53 alteration in NSCLC patients.

In summary, null mutation were an independent significant prognostic factor in p stage I NSCLC patients. The mutation accounted for a significant proportion of p53 mutations and could not be detected by immunohistochemistry. Analysis of p53 mutational type is warranted to predict the clinical course of stage I NSCLC patients undergoing radical surgery; it also allows optional choices of innovative therapies.


   ACKNOWLEDGMENTS
 
We thank Drs. H. Sugano (Cancer Institute) and K. Nakachi, K. Imai, and T. Kozu (Saitama Cancer Center Research Institute) for their helpful advice and discussions. We also thank Dr. S. Okumura for kindly providing human tissues and clinical data. The technical assistance of T. Yoshikawa and Y. Yamaoka is gratefully acknowledged.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by grants-in-aid for scientific research from the Ministry of Education, Science, Sports, and Culture of Japan; by a research grant from the Ministry of Health and Welfare of Japan; and by the Vehicle Racing Commemorative Foundation. Back

2 To whom requests for reprints should be addressed, at Saitama Cancer Center Research Institute, 818, Komuro, Ina, Kitaadachi-gun, Saitama 362-0806, Japan. Phone: 81-48-722-1111; Fax: 81-48-722-1739; E-mail: etuchiya{at}cancer-c.pref.saitama.jp Back

3 The abbreviations used are: NSCLC, non-small cell lung carcinoma; SSCP, single-strand conformation polymorphism. Back

Received 5/19/99. Accepted 6/ 9/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Parkin D. M., Pisani P., Ferlay J. Estimates of the world wide incidence of eighteen major cancers in 1985. Int. J. Cancer, 54: 594-606, 1993.[Medline]
  2. Travis W. D., Travis L. B., Devesa S. S. Lung cancer. Cancer (Phila.), 75 (Suppl 1): 191-202, 1995.[Medline]
  3. Ministry of Health and Welfare. Statistics and Information Department. Vital statistics 1990 Japan. Tokyo: Ministry of Health and Welfare, 1997.
  4. WHO The World Health Organization histological typing of lung tumors ed. 2. . Am. J. Clin. Pathol., 77: 123-136, 1982.[Medline]
  5. Naruke T., Goya T., Tsuchiya R., Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J. Thorac. Cardiovasc. Surg., 96: 440-447, 1988.[Abstract]
  6. Lane D. P. p53, guardian of the genome. Nature (Lond.), 358: 15-16, 1992.[Medline]
  7. Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. New Engl. J. Med., 329: 1318-1327, 1993.[Free Full Text]
  8. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.[Free Full Text]
  9. Nigro J. M., Baker S. J., Preisinger A. C., Jessup J. M., Hostetter R., Cleary K., Bigner S. H., Davidson N., Baylin S., Devilee P., Glover T., Collins F. S., Weston A., Modali R., Harris C. C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumor types. Nature (Lond.), 342: 705-708, 1989.[Medline]
  10. Takahashi T., Nau M. M., Chiba I., Birrer M. J., Rosenberg R. K., Vinocour M., Levitt M., Pass H., Gazdar A. F., Minna J. D. p53: a frequent target for genetic abnormalities in lung cancer. Science (Washington DC), 246: 491-494, 1989.[Abstract/Free Full Text]
  11. Iggo R., Gatter K., Bartek J., Lane D., Harris A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 335: 675-679, 1990.[Medline]
  12. Hartmann A., Blaszyk H., McGovern R. M., Schroeder J. J., Cunningham J., De Vries E. M., Kovach J. S., Sommer S. S. p53 gene mutations inside and outside of exons 5–8: the patterns differ in breast and other cancers. Oncogene, 10: 681-688, 1995.[Medline]
  13. Casey G., Lopez M. E., Ramos J. C., Plummer S. J., Arboleda M. J., Shaughnessy M., Karlan B., Slamon D. DNA sequence analysis of exon 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene, 13: 1971-1981, 1996.[Medline]
  14. Bodner S. M., Minna J. D., Jensen S. M., D’Amico D., Carbone D., Mitsudomi T., Fedorko J., Buchhagen D. L., Nau M. M., Gazdar A. F., Linnoila R. I. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7: 743-749, 1992.[Medline]
  15. Quinlan D. C., Davidson A. G., Summers C. L., Warden H. E., Doshi H. M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52: 4828-4831, 1992.[Abstract/Free Full Text]
  16. McLaren R., Kuzu I., Dunnill M., Harris A., Lane D., Gatter K. C. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br. J. Cancer, 66: 735-738, 1992.[Medline]
  17. Brambilla E., Gazzeri S., Moro D., De Fromentel C. C., Gouyer V., Jacrot M., Brambilla C. Immunohistochemical study of p53 in human lung carcinomas. Am. J. Pathol., 143: 199-210, 1993.[Abstract]
  18. Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R., Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl. Cancer Inst., 85: 2018-2023, 1993.[Abstract/Free Full Text]
  19. Fong K. M., Kida Y., Zimmerman P. V., Ikenaga M., Smith P. Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer. Cancer Res., 55: 4268-4272, 1995.[Abstract/Free Full Text]
  20. Carbone D. P., Mitsudomi T., Chiba I., Piantadosi S., Rusch V., Nowak J. A., McIntire D., Salmon D., Gazdar A., Minna J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest, 106: 377S-381S, 1994.[Medline]
  21. Ebina M., Steinberg S. M., Mulshine J. L., Linnoila R. I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res., 54: 2496-2503, 1994.[Abstract/Free Full Text]
  22. Harpole D. H., Jr., Marks J. R., Richards W. G., Herndon J. E., II, Sugarbaker D. J. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin. Cancer Res., 1: 659-664, 1995.[Abstract]
  23. Lee J. S., Yoon A., Kalapurakal S. K., Ro J. Y., Lee J. J., Tu N., Hittelman W. N., Hong W. K. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J. Clin. Oncol., 13: 1893-1903,
  24. Nishio M., Koshikawa T., Kuroishi T., Suyama M., Uchida K., Takagi Y., Washimi O., Sugiura T., Ariyoshi Y., Takahashi T., Ueda R., Takahashi T. Prognostic significance of abnormal p53 accumulation in primary non-small-cell lung cancers. J. Clin. Oncol., 14: 497-502, 1996.[Abstract/Free Full Text]
  25. Pastorino U., Andreola S., Tagliabue E., Pezzella F., Incarbone M., Sozzi G., Buyse M., Menard S., Pierotti M., Rilke F. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J. Clin. Oncol., 15: 2858-2865, 1997.[Abstract]
  26. Vega F. J., Iniesta P., Caldés T., Sánchez A., López J. A., De Juan C., Diaz-Rubio E., Torres A., Balibrea J. L., Benito M. p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer. Br. J. Cancer, 76: 44-51, 1997.[Medline]
  27. De Anta J. M., Jassem E., Rosell R., Martínez-Roca M., Jassem J., Martínez-López E., Monzó M., Sánchez-Hernández J. J., Moreno I., Sánchez-Céspedes M. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene, 15: 2951-2958, 1997.[Medline]
  28. Tomizawa Y., Kohno T., Fujita T., Kiyama M., Saito R., Noguchi M., Matsuno Y., Hirohashi S., Yamaguchi N., Nakajima T., Yokota J. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene, 18: 1007-1014, 1999.[Medline]
  29. Dix B., Robbins P., Carrello S., House A., Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br. J. Cancer, 70: 585-590, 1994.[Medline]
  30. Mineta H., Borg Å., Dictor M., Wahlberg P., Åkervall J., Wennerberg J. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br. J. Cancer, 78: 1084-1090, 1998.[Medline]
  31. Union Internationale Contre le Cancer (UICC) Lung tumors 4th ed. Hermanek P. Sobin L. H. eds. . TNM Classification of Malignant Tumors, : 70-73, Springer-Verlag Berlin 1987.
  32. Tsuchiya E., Nakamura Y., Weng S-Y., Nakagawa K., Tsuchiya S., Sugano H., Kitagawa T. Allelotype of non-small cell lung carcinoma: comparison between loss of heterozygosity in squamous cell carcinoma and adenocarcinoma. Cancer Res., 52: 2478-2481, 1992.[Abstract/Free Full Text]
  33. Orita M., Iwahana H., Kanazawa H., Hayashi K., Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci. USA, 86: 2766-2770, 1989.[Abstract/Free Full Text]
  34. Tokuchi Y., Hashimoto T., Kobayashi Y., Hayashi M., Nishida K., Hayashi S., Imai K., Nakachi K., Ishikawa Y., Nakagawa K., Kawakami Y., Tsuchiya E. The expression of p73 is increased in lung cancer, independent of p53 gene alteration. Br. J. Cancer, 80: 1623-1629, 1999.[Medline]
  35. Kawai K., Noguchi M., Beppu Y., Yokoyama R., Mukai K., Hirohashi S., Inoue H., Fukuma H. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor. Cancer (Phila.), 73: 2499-2505, 1994.[Medline]
  36. Nakanishi K., Kawai T., Torikata C. Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract. Hum. Pathol., 27: 1336-1340, 1996.[Medline]
  37. Kawasaki M., Noguchi M., Morikawa A., Matsuno Y., Yamada T., Hirohashi S., Kondo H., Shimosato Y. Nuclear p53 accumulation by small-sized adenocarcinomas of the lung. Pathol. Int., 46: 486-490, 1996.[Medline]
  38. Matlashewsky G. J., Tuck S., Pim D., Lamb P., Schneider J., Crawford L. V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol., 7: 961-963, 1987.[Abstract/Free Full Text]
  39. Kishimoto Y., Murakami Y., Shiraishi M., Hayashi K., Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res., 52: 4799-4804, 1992.[Abstract/Free Full Text]
  40. Selivanova G., Iotsova V., Okan I., Fritsche M., Ström M., Groner B., Grafström R. C., Wiman K. G. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med., 3: 632-638, 1997.[Medline]
  41. Zhou X., Wang X. W., Xu L., Hagiwara K., Nagashima M., Wolkowicz R., Zurer I., Rotter V., Harris C. C. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Res., 59: 843-848, 1999.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. M. Mulligan, D. Pinnaduwage, S. B. Bull, F. P. O'Malley, and I. L. Andrulis
Prognostic Effect of Basal-Like Breast Cancers Is Time Dependent: Evidence from Tissue Microarray Studies on a Lymph Node-Negative Cohort
Clin. Cancer Res., July 1, 2008; 14(13): 4168 - 4174.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A Psyrri, P Kountourakis, Z Yu, C Papadimitriou, S Markakis, R. Camp, T Economopoulos, and M. Dimopoulos
Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets
Ann. Onc., April 1, 2007; 18(4): 709 - 715.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda
Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review
Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Camp, M. Dolled-Filhart, and D. L. Rimm
X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization
Clin. Cancer Res., November 1, 2004; 10(21): 7252 - 7259.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pathol.Home page
F Bataille, P Rummele, W Dietmaier, D Gaag, F Klebl, A Reichle, P Wild, F Hofstadter, and A Hartmann
Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer
Mol. Pathol., October 1, 2003; 56(5): 286 - 292.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. L. Rose, A. D. Robertson, M. J. Goodheart, B. J. Smith, B. R. DeYoung, and R. E. Buller
The Impact of p53 Protein Core Domain Structural Alteration on Ovarian Cancer Survival
Clin. Cancer Res., September 15, 2003; 9(11): 4139 - 4144.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Allegra, S. Paik, L. H. Colangelo, A. L. Parr, I. Kirsch, G. Kim, P. Klein, P. G. Johnston, N. Wolmark, and H. S. Wieand
Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study
J. Clin. Oncol., January 15, 2003; 21(2): 241 - 250.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
R.-S. Lai, J.-S. Wang, H.-K. Hsu, H.-C. Chang, C.-H. Lin, and M.-H. Lin
Prognostic Evaluation of the Expression of p53 and bcl-2 Oncoproteins in Patients with Surgically Resected Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., October 1, 2002; 32(10): 393 - 397.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. D. Brundage, D. Davies, and W. J. Mackillop
Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress
Chest, September 1, 2002; 122(3): 1037 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Allegra, A. L. Parr, L. E. Wold, M. R. Mahoney, D. J. Sargent, P. Johnston, P. Klein, K. Behan, M. J. O'Connell, R. Levitt, et al.
Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer
J. Clin. Oncol., April 1, 2002; 20(7): 1735 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Koga, S. Hashimoto, K. Sugio, I. Yoshino, S. Mojtahedzadeh, Y. Matsuo, Y. Yonemitsu, K. Sugimachi, and K. Sueishi
Clinicopathological and Molecular Evidence Indicating the Independence of Bronchioloalveolar Components from Other Subtypes of Human Peripheral Lung Adenocarcinoma
Clin. Cancer Res., June 1, 2001; 7(6): 1730 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Okuda, H. Osugi, K. Morimura, N. Takada, M. Takemura, S. Fukushima, M. Higashino, and H. Kinoshita
Detection of p53 Gene Mutations in Human Esophageal Squamous Cell Carcinomas Using a p53 Yeast Functional Assay: Possible Difference in Esophageal Carcinogenesis Between the Young and the Elderly Group
Clin. Cancer Res., March 1, 2001; 7(3): 600 - 606.
[Abstract] [Full Text]

Home page
 Am. J. Pathol.Home page
T. Hashimoto, Y. Tokuchi, M. Hayashi, Y. Kobayashi, K. Nishida, S.-i. Hayashi, Y. Ishikawa, K. Nakagawa, J.-i. Hayashi, and E. Tsuchiya
Different Subtypes of Human Lung Adenocarcinoma Caused by Different Etiological Factors : Evidence from p53 Mutational Spectra
Am. J. Pathol., December 1, 2000; 157(6): 2133 - 2141.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Grundei, H. Vogelsang, K. Ott, J. Mueller, M. Scholz, K. Becker, U. Fink, J. R. Siewert, H. Höfler, and G. Keller
Loss of Heterozygosity and Microsatellite Instability as Predictive Markers for Neoadjuvant Treatment in Gastric Carcinoma
Clin. Cancer Res., December 1, 2000; 6(12): 4782 - 4788.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
T. Hashimoto, Y. Kobayashi, Y. Ishikawa, S. Tsuchiya, S. Okumura, K. Nakagawa, Y. Tokuchi, M. Hayashi, K. Nishida, S.-i. Hayashi, et al.
Prognostic Value of Genetically Diagnosed Lymph Node Micrometastasis in Non-Small Cell Lung Carcinoma Cases
Cancer Res., November 1, 2000; 60(22): 6472 - 6478.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
M. G. C. T. van Oijen and P. J. Slootweg
Gain-of-Function Mutations in the Tumor Suppressor Gene p53
Clin. Cancer Res., June 1, 2000; 6(6): 2138 - 2145.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hashimoto, T.
Right arrow Articles by Tsuchiya, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hashimoto, T.
Right arrow Articles by Tsuchiya, E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online